ClinicalTrials.Veeva

Menu

Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma

G

Groupe Oncologie Radiotherapie Tete et Cou

Status and phase

Completed
Phase 3

Conditions

Hypopharynx Cancer
Larynx Cancer

Treatments

Drug: DOCETAXEL
Drug: Cisplatin
Drug: 5-Fluoro-3-Pyridinecarboxylic Acid

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT00169182
GORTEC 2000-01

Details and patient eligibility

About

The purpose of the study is to compare two regimen of chemotherapy used as first treatment for patients with larynx or hypopharynx tumors that would be treated with total laryngectomy. The standard treatment is a combination of 2 drugs (Cisplatin and 5FU). The aim of the study is to evaluate the potential benefit of the addition of a third drug (Docetaxel) in the chemotherapy regimen. Patients will receive 3 cycles of chemotherapy. Responders to the induction treatment are treated with radiation with a purpose of larynx preservation. Non responders patients will be treated with total laryngectomy.

Full description

The purpose of the study is to compare two regimen of induction chemotherapy for patients with T3 and T4 larynx or hypopharynx carcinoma that would be treated with total laryngectomy. The aim of the study is to compare the standard regimen (Cisplatin + 5FU) versus the TPF regimen (Taxotere + Cisplatin + 5FU). Responders to the induction treatment are treated with radiation with a purpose of larynx preservation. Non responders patients will be treated with total laryngectomy followed by postoperative radiation.

Enrollment

220 patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • T3 and T4 larynx and hypopharynx tumor that would be treated with total laryngectomy
  • Biopsy proven carcinoma
  • Adequate biology
  • Performance status 0 or 1

Exclusion criteria

  • Larynx or hypopharynx tumors that could be treated with partial laryngectomy
  • Distant metastasis
  • Prior surgery, chemotherapy or radiation
  • Intercurrent disease that is a contra indication to chemotherapy

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

220 participants in 2 patient groups

TPF
Experimental group
Description:
Docetaxel, Cisplatine, 5-FU
Treatment:
Drug: Cisplatin
Drug: DOCETAXEL
Drug: 5-Fluoro-3-Pyridinecarboxylic Acid
PF
Active Comparator group
Description:
Cisplatine, 5-FU
Treatment:
Drug: Cisplatin
Drug: 5-Fluoro-3-Pyridinecarboxylic Acid

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems